These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effects of dalcetrapib in patients with a recent acute coronary syndrome. Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS; N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252 [TBL] [Abstract][Full Text] [Related]
5. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Brown BG; Zhao XQ Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243 [TBL] [Abstract][Full Text] [Related]
6. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C; Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528 [TBL] [Abstract][Full Text] [Related]
7. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264 [TBL] [Abstract][Full Text] [Related]
8. Dalcetrapib: a review of Phase II data. Robinson JG Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364 [TBL] [Abstract][Full Text] [Related]
9. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
16. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. Wright RS Curr Opin Cardiol; 2013 Jul; 28(4):389-98. PubMed ID: 23736814 [TBL] [Abstract][Full Text] [Related]
17. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? Ahmed MH J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417 [TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein levels and risk of cardiovascular events: a review. Mureddu GF; Brandimarte F; De Luca L J Cardiovasc Med (Hagerstown); 2012 Sep; 13(9):575-86. PubMed ID: 21986488 [TBL] [Abstract][Full Text] [Related]
19. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. Lim S; Park YM; Sakuma I; Koh KK Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572 [TBL] [Abstract][Full Text] [Related]
20. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. Duvall WL; Blazing MA; Saxena S; Guyton JR J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]